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Abstract
Background: Being overweight is associated with both higher systolic blood pressure (SBP) and diastolic
blood pressure (DBP) during pregnancy and increased risk of gestational hypertensive disorders. The objective
of this study was to determine and quantify the effect of body mass index (BMI) on mean arterial pressure
(MAP) at several time points throughout pregnancy in normotensive (NT) and chronic hypertensive pregnant
(HT) women.
Methods: A prospective longitudinal study was carried out in 461 singleton pregnancies (429 low-risk and 32
with chronic arterial hypertension), with measurements taken at the 1st, 2nd, and 3rd trimesters and at
delivery. Linear mixed-effects regression models were used to evaluate the time-progression of BMI, SBP, DBP
and MAP during pregnancy (NT vs. HT). The longitudinal effect of BMI on MAP, adjusted for the hypertensive
status, was investigated by the same methodology.
Results: BMI consistently increased with time in both NT and HT women. In contrast, MAP decreased during
the first half of pregnancy, after which it increased until the moment of delivery in both groups. A 5-unit
increase in BMI was predicted to produce an increase of approximately 1 mmHg in population MAP values.
This effect is independent from the time period and from hypertensive status.
Conclusions: In both NT and HT pregnant women, MAP is strongly (and significantly) influenced by increases in BMI.
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Background
Chronic arterial hypertension is a serious disorder; if left
untreated, it can lead to serious health outcomes, mostly
affecting target organs such as the heart, brain, kidney
and retina [1].
Women diagnosed with hypertension who become
pregnant are at an increased risk for several preg-
nancy complications, including superimposed pre-
eclampsia [2, 3], foetal growth restriction [4], preterm
delivery [5], placental abruption [6], and caesarean
section [3, 5]. In addition, because chronic arterial
hypertension affects 3–5 % of pregnancies [7, 8], it
alone is a matter of concern and is increasingly en-
countered [3]. Obesity is the main risk factor contrib-
uting to this increased prevalence; its frequency is
increasing among pregnant women, and it is a well-
known risk factor for both adverse maternal [9] and
neonatal outcomes [10, 11]. In fact, increased adipos-
ity during normal pregnancy has been consistently as-
sociated with the same medical complications that are
associated with chronic arterial hypertension in preg-
nant women (as described above) [12]. However, the
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mechanisms for these associations are not completely
understood.
Several studies have examined the effects of mater-
nal weight on blood pressure levels during different
periods of normal pregnancy [10, 13–16]. The results
suggest that overweight, obesity and morbid obesity
are associated with higher systolic (SBP) and diastolic
blood pressure (DBP) during pregnancy and increased
risks of gestational hypertensive disorders [9].
Nevertheless, studies that have effectively quantified
the effects of weight gain on maternal blood pressure
during pregnancy are lacking. It has been reasoned
that additional data on the effects of increased body
mass index (BMI) on mean arterial pressure (MAP)
during normal pregnancy would be provided by a
parallel study in women with long-term stable essen-
tial hypertension, which is a prevalent condition and
a known risk factor for serious gestational disorders
[5, 7, 17].
Based on these considerations, this study aimed to de-
termine and quantify the effects of BMI on MAP at sev-
eral time points throughout pregnancy, in normotensive
(NT) and chronic hypertensive (HT) pregnant women.
Methods
Ethics
The research protocol was approved by the local
ethics committee (IRB protocol number: 133/10
[086-DEFI/126-CES]) of the Centro Hospitalar do
Porto – Unidade Maternidade Júlio Dinis (CHP-
MJD), and all of the subjects provided written con-
sent upon receiving an adequate explanation of the
study. The methods were carried out in accordance
with the approved protocol.
Study population and design
Between January 2010 and December 2012 a total of 578
pregnant Caucasian women were recruited to participate
in the study. According to local pregnancy health pol-
icies, the women were referred by their family doctors to
the CHP-MJD.
During their first appointment the women were ob-
served by a senior specialist who reviewed their med-
ical history, verified the absence of diabetes and
other endocrine disorders, immune diseases, renal
diseases, structural heart diseases, haematological
conditions and chronic infections; gestational age
(GA) was also checked by ultrasonography between
11 and 14 weeks [18].
The inclusion criteria were as follows: (1) singleton
pregnancy and gestational age ≤ 14 weeks, and (2)
healthy status or stable chronic arterial hypertension
without known target organ involvement.
The exclusion criteria were as follows: (1) patients
with multiple gestations, coagulopathy, haematological
pathology, diabetes, or any pregnancy-induced hyperten-
sion including preeclampsia, and (2) patients who re-
fused to participate. Subjects were also excluded from
the study if they had a preterm delivery (birth < 37th ges-
tational week), were lost to follow-up, needed antihyper-
tensive medication, or experienced foetal death.
Chronic arterial hypertension was defined as a
blood pressure of 140/90 mmHg on more than two
occasions before 20 weeks of gestation or after
20 weeks of pregnancy if it persisted beyond 12 weeks
postpartum [17].
Before pregnancy, the majority of the hypertensive
patients required multiple medications, including thia-
zide, angiotensin converting enzyme inhibitor, angio-
tensin receptor blockers, or calcium channel blockers,
to control their hypertension. After their first appoint-
ment, antihypertensive drugs were discontinued, and
their blood pressure was closely monitored. Antihy-
pertensive therapy was restarted if a patient experi-
enced a persistent diastolic pressure between 95 and
99 mmHg or if a systolic pressure ≥ 150 mmHg was
observed at any time during their pregnancy. For
women with chronic hypertension who enter preg-
nancy not on antihypertensive treatment, the antihy-
pertensive treatment was initiated when blood
pressures were consistently > 160 mmHg systolic and/
or > 105 mmHg diastolic [17].
Definition of time-point measurements
Anthropometric parameters and blood pressure were
measured at the following four time points: 12–14
weeks, 18–22 weeks, 29–33 weeks, and delivery. Each of
these time points were converted to a time scale ranging
from 0 to 1. Therefore, the initial time (i.e., before preg-
nancy) was considered to be time = 0, and the time of
delivery was considered to be time = 1.
Maternal anthropometrics
The height (cm) and weight (kg) of each subject were
measured without heavy clothing and shoes at each
time point. Data about maternal weight just before
pregnancy was obtained through questionnaires. Pre-
pregnancy body mass index (BMI) was categorized
into the following three categories: lean or normal
(16–24 kg/m2), overweight (25–29 kg/m2) and obese
(30–50 kg/m2).
Blood pressure assessment
The blood pressure (BP) was measured using an auto-
mated instrument (GE Healthcare Carescape™ V100
Vital Signs Monitor with DINAMAP Technology,
Milwaukee, WI, USA); it was measured two consecutive
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times and averaged. Mean arterial pressure (MAP) was
obtained according to the following formula:
MAP ¼ 2 diastolic pressureð Þ þ systolic pressure
3
Prior to the measurement, each of the participants was
seated and asked to relax for 5–10 min. A cuff (CRITI-
KON Blood Pressure Cuffs®, GE Healthcare, 23–33 cm,
Milwaukee, WI, USA) was placed around the non-
dominant upper arm at the level of the heart, with the
pressure cuff bladder midline over the brachial artery. A
larger cuff (32–42 cm) was used in patients who had an
upper arm that exceeded 33 cm. As enrolment in our
study took place during pregnancy, we were unable to
measure maternal blood pressure before pregnancy.
Definition of normal pregnancy
To restrict enrolment to patients with normal course
pregnancies, we excluded 117 (20.2 %) pregnant women
who experienced any of the following events during their
pregnancies: endocrine disorders, psychiatric disorders,
history of bariatric surgery, secondary hypertension, gesta-
tional hypertension/preeclampsia, preterm delivery, foetal
growth restriction, antihypertensive medication use, mul-
tiple gestation, and foetal death. After these exclusions,
461 women who had a normal pregnancy remained.
Therefore, the study used basic inclusion criteria, includ-
ing patients who were healthy or had stable chronic
hypertension without known target organ involvement.
Efforts to address potential sources of bias
Any pregnant women who were seen by our clinical in-
vestigator during the study period were considered to be
potentially eligible. The pregnancy consultations were
randomly scheduled by the hospital administrative staff
according to the availability of the clinical investigator
(L.G-M.). The patients were consecutively recruited, and
the maternal anthropometric and blood pressure mea-
surements were taken by experienced midwives who
were aware of the study protocol. All of the pregnancies
were supervised by the same physician (L.G-M.), but the
inclusion of pregnancies in the study was determined by
another researcher who coordinated the review of each
clinical case (A.C.).
Statistical analysis
Univariate analyses included the following standard
statistical methods: (1) the chi-square or Fisher’s exact
tests to compare frequencies from categorical
variables or to study the independence between two
factors; and (2) t-tests to assess the statistical signifi-
cance of the difference between the means of two in-
dependent populations.
Time was considered a continuous variable, with
values 0, 0.3, 0.5, 0.8 and 1, in the BMI model [respect-
ively 0.3, 0.5, 0.8 and 1 in the systolic blood pressure
(SBP), diastolic blood pressure (DBP), MAP, and BMI ef-
fect on MAP (MAP-BMI) models]. Whilst 0 and 1 were
arbitrarily chosen, the other points were proportional to
the observational periods in the study; namely, before
pregnancy, 12–14 weeks, 18–22 weeks, 29–33 weeks,
and at delivery. Hypertension was a binary variable with
normotensive status as the reference category.
Linear mixed-effects (regression) models were used with
the observations grouped at the individual level [19]. The
random effects in the final models were identified either
at the intercept alone, or at the intercept and the time co-
efficient. In the final models with two random effects, the
best structure for the variance-covariance matrix of the
random effects was shown to be that of a general positive
definite matrix. Whenever the within-group error variance
function had to be modelled, the assumption of independ-
ence did not seem to be compromised. For the same indi-
vidual, the errors were assumed to be independent from
the random effects; for different individuals, the er-
rors were assumed to be independent. The normality
assumptions for the random effects and errors distribu-
tions were assessed through graphical analysis; however,
for the BMI-time model, the responses had to be log-
transformed for the normality of the errors distribution to
not be rejected, and the normality assumption within the
remaining models was confirmed. Due to sample size con-
straints, interaction terms were only considered in the
MAP-BMI model.
The final models were chosen based on the lowest
Bayesian information criterion (BIC) or on the likelihood
ratio test, as appropriate. All statistical analyses were
carried out using R version 2.12.1 [20]. The significance
level was set at 0.05.
Results
Of the 461 women who were enrolled in the study, 429
were normotensive and 32 had chronic arterial
hypertension.
Figure 1 shows the number of pregnant women at
each stage of the study. The main characteristics and
pregnancy outcomes are shown in Table 1. In 31.9 % of
the cases, caesarean section was the mode of delivery; in
more than 70 % of those cases, the reason for receiving
a caesarean section was prior caesarean delivery, dys-
tocia, foetal distress, or breech presentation (Table 2).
Table 3 describes the maternal anthropometrics and
blood pressure during the study period. BMI consist-
ently increased over time in both the NT and HT
groups. In contrast, MAP decreased during the first
half of pregnancy and then increased until the mo-
ment of delivery.
Guedes-Martins et al. BMC Pregnancy and Childbirth  (2015) 15:281 Page 3 of 13
Fig. 1 Study flowchart: number of pregnant women at each stage of the study. *Any pregnant women who were seen by our clinical investigator
during the study period were considered to be potentially eligible
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Table 1 Demographic characteristics and pregnancy outcomes of the 461 women included in the analysis
Normotensive Hypertensive BMI (kg/m2)
n (%) p-value* n = 429 n = 32 p-value** 16–24 25–29 30–50 p-value***
Age years [years (%)] 16–24 102 (22 %) <0.001 102 (24 %) 0 <0.001 66 (26 %) 20 (17 %) 16 (18 %) 0.047
25–35 303 (66 %) 285 (66 %) 18 (56 %) 164 (65 %) 78 (66 %) 61 (67 %)
36–43 56 (12 %) 42 (10 %) 14 (44 %) 22 (9 %) 20 (17 %) 14 (15 %)
Parity [n (%)] 0 238 (52 %) 0.485 226 (53 %) 12 (38 %) 0.140 135 (54 %) 54 (46 %) 49 (54 %) 0.335
≥1 223 (48 %) 203 (47 %) 20 (62 %) 117 (46 %) 64 (54 %) 42 (46 %)
Gestational age at delivery,
weeks [mean (SD)]
39.22 (1.20) - NA 39.24 (1.17) 38.93 (1.68) 0.308 39.21 (1.18) 39.20 (1.28) 39.25 (1.22) 0.960
Foetal sex [n (%)] Female 245 (53 %) 0.177 229 (53 %) 16 (50 %) 0.852 129 (51 %) 62 (53 %) 54 (59 %) 0.405
Male 216 (47 %) 200 (47 %) 16 (50 %) 123 (49 %) 56 (47 %) 37 (41 %)
Birth weight at delivery,
g [mean (SD)]
3128 (334) - NA 3136 (329) 3007 (379) 0.070 3116 (350) 3167 (321) 3108 (301) 0.042
Apgar Score Index at 5′ <7 0 NA 0 (0 %) 0 (0 %) <0.001 0 0 0 <0.001
7–10 461 (100 %) 429 (100 %) 32 (100 %) 252 (100 %) 118 (100 %) 91 (100 %)
BMI body mass index, SD standard deviation
*p - tested equality of population frequencies amongst the different categories of a variable
**p - tested homogeneity of the proportions between HT (hypertensive) and NT (normotensive)
***p - tested homogeneity of the proportions between normal weight, overweight and obese
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BMI model
The longitudinal model for BMI estimated a quadratic
progression during pregnancy, with the same progres-
sion rate for both the NT and HT groups (Fig. 2).
The model for the BMI evolution during pregnancy,
for any given rescaled time t and hypertensive status h
(equal to 1 for HT and 0 for NT) of the ith woman, was
as follows:
log BMIið Þ t; hð Þ ¼ β0 þ b0i þ β1hþ β2t þ β3t2 þ εi ð1Þ
where the random effect b0i was assumed to follow a nor-
mal distribution, and the within-group error terms εi were
assumed to follow a multivariate (5-dimensional) normal
distribution with a first-order autoregressive model for
their correlation structure. The corresponding estimates
are presented in Table 4. The estimates for the correlation
parameter (95 % CI) and the within-group standard error
(95 % CI) were 0.943 (0.795, 0.985) and 0.103 (0.053,
0.198), respectively. All fixed effects are multiplicative be-
cause the response was log-transformed.
The predicted BMI change during pregnancy consists of
two increasing parabolic branches for each hypertensive
status that are significantly different from one another; for
any given time, the model predicts the hypertensive popu-
lation to have a mean BMI that is significantly greater
than that of the normotensive population.
SBP model
The model for SBP during pregnancy, for any given
rescaled time t and hypertensive status h of the ith
woman, was as follows:
SBPi t; hð Þ ¼ β0 þ b0i
 þ β1hþ β2 þ b1ið Þt
þ β3t2 þ β4t3 þ εi ð2Þ
where the random effects b0i; b1ið Þ were assumed to fol-
low a bivariate normal distribution with a general
positive-definite variance-covariance matrix, and the
Table 3 Description of maternal anthropometrics and blood
pressure at each study period
Period Normotensive Hypertensive
Weight kg, mean (SD) Pre-pregnancy 64.09 (12.65) 75.17 (17.06)
12–14 weeks 65.94 (13.03) 76.83 (17.67)
18–22 weeks 69.82 (13.69) 78.69 (16.96)
29–33weeks 75.92 (13.99) 85.03 (16.34)
At delivery 80.96 (14.12) 92.95 (16.93)
BMI kg/m2, mean (SD) Pre-pregnancy 25.10 (5.18) 28.76 (6.54)
12–14 weeks 25.83 (5.38) 29.40 (6.79)
18–22 weeks 27.35 (5.66) 30.12 (6.52)
29–33weeks 29.75 (5.86) 32.56 (6.39)
At delivery 31.73 (5.98) 35.59 (6.59)
SBP mmHg, mean (SD) Pre-pregnancy - -
12–14 weeks 119.79 (10.62) 136.22 (9.36)
18–22 weeks 114.37 (10.28) 123.65 (9.29)
29–33weeks 119.91 (11.03) 140.81 (8.52)
At delivery 121.50 (11.66) 143.75 (8.84)
DBP mmHg, mean (SD) Pre-pregnancy - -
12–14 weeks 63.05 (8.15) 76.09 (6.89)
18–22 weeks 64.09 (11.44) 72.62 (6.84)
29–33weeks 62.93 (10.85) 78.94 (8.05)
At delivery 66.13 (11.54) 76.88 (9.21)
MAP mmHg, mean (SD) Pre-pregnancy - -
12–14 weeks 81.96 (6.75) 96.14 (6.01)
18–22 weeks 80.85 (8.52) 86.64 (4.45)
29–33weeks 81.93 (8.28) 99.56 (6.45)
At delivery 84.59 (8.82) 99.16 (6.91)
BMI body mass index, SBP systolic blood pressure, DBP diastolic blood
pressure, MAP mean arterial pressure, SD standard deviation
Table 2 Indication for caesarean sections (n = 147) in the study sample
Caesarean deliveries (%)a
All (%) Normotensive (%) Hypertensive (%)
n = 147 n = 135b n = 12c
Primary Dystocia 29 (20) 27 (20) 2 (17)
Non-reassuring foetal heart rate 21 (14) 19 (14) 2 (17)
Abnormal presentation 18 (12) 17 (13) 1 (8)
Unsuccessful trial of forceps or vacuum 14 (10) 13 (10) 1 (8)
Repeat No VBAC attempt 40 (27) 36 (27) 4 (33)
Failed VBAC 16 (11) 15 (11) 1 (8)
Unsuccessful trial of forceps or vacuum 9 (6) 8 (6) 1 (8)
aData are shown as absolute (relative, %) frequencies
The sums of the relative frequencies in the categories were 101 %b and 99 % c due to rounding
VBAC vaginal birth after caesarean
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within-group error terms εi were assumed to follow a
multivariate (4-dimensional) normal distribution. The
estimates of the effects are presented in Table 4. The er-
rors were found to have a variance function that is an
exponent of the fitted values, with a coefficient (95 %
CI) estimated to be −0.031 (−0.037, −0.025). The correl-
ation coefficient (95 % CI) between the random effects
was estimated to be −0.855 (−0.887, −0.815).
Two cubic parallel curves were obtained, one for each
hypertensive status, and the SBP predictions were sig-
nificantly higher for the HT group than the NT (Fig. 3).
For the normotensive population, the minimum and
maximum expected values were 113.5 mmHg and
123.9 mmHg, respectively, and they were attained at the
(rescaled) time = 0.49 and time = 0.93, respectively. For the
hypertensive population, the minimum and maximum
mean values (attained at the same times) were predicted
to be 129.5 mmHg and 139.9 mmHg, respectively.
DBP model
The model for DBP during pregnancy was of a similar
form to (2). The obtained estimates for its effects are pre-
sented in Table 4. The correlation coefficient (95 % CI) be-
tween the random effects was estimated to be −0.831
(−0.882, −0.760). The variance-covariance matrix of the
within group errors was diagonal with a variance function
that was constant for the hypertensive and normotensive
groups. When the error variance within the normotensive
population was standardized to 1, the estimated variance
(95 % CI) of the hypertensive population was 0.691 (0.581,
0.821) times the variance prior to standardization.
Two cubic parallel curves were expected, and the DBP
values were significantly higher for the HT group than the
NT group (Fig. 3). For the normotensive population, the
minimum and maximum mean values were predicted to
be 63.21 mmHg and 66.38 mmHg, respectively, and they
were attained at t = 0.64 and t = 1, respectively. For the
hypertensive population, the minimum and maximum
mean values (attained at the same times) were predicted
to be 75.16 mmHg and 78.34 mmHg, respectively.
MAP model
The model for MAP during pregnancy was again of a simi-
lar form to (2). Its estimates are presented in Table 4. The
correlation coefficient (95 % CI) between the two random-
effects was estimated to be −0.871 (−0.828, −0.772). The
variance-covariance matrix of the within group errors was
diagonal with a power variance function based on the fit-
ted values; the variance function coefficient (95 % CI) was
estimated to be −1.632 (−2.206, −1.058).
For the MAP model, two cubic parallel curves, one for
each hypertensive status, were predicted, and the MAP
values were significantly higher in the hypertensive
group than the normotensive group (Fig. 4). Between
12–14 weeks, the average MAP values were 82.42 mmHg
and 95.43 mmHg in the NT and HT groups, respectively.
The values decreased during weeks 18–22, reaching a
minimum of 80.43 mmHg and 93.44 mmHg in the NT
and HT groups, respectively. After week 22, the values
Fig. 2 Expected body mass index (BMI) over time in the hypertensive (triangles) and normotensive (circles) women. The 95 % confidence
intervals for the respective predictions are indicated (dashed lines)
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increased until delivery, reaching a maximum of
85.05 mmHg and 98.06 mmHg, respectively.
Adjusted BMI effect on MAP (MAP-BMI Model)
The effect of BMI on MAP was obtained by adjusting the
previous MAP model for the time-dependent BMI vari-
able. The estimates obtained for the model effects are pre-
sented in Table 4. The correlation coefficient (95 % CI)
between the random effects was estimated to be −0.832
(−0.875, −0.776). The variance-covariance matrix of the
within group errors was diagonal with a variance
function that was a power of the fitted values; the
variance function coefficient (95 % CI) was estimated
to be −1.740 (−2.300, −1.180).
The interaction between hypertensive status and BMI
was not statistically significant (p = 0.275). Adjusting for
BMI led to very similar conclusions regarding the time
and the hypertension effects on MAP. With respect to
the BMI effect, a 1-unit increase in BMI was predicted
to produce an increase of 0.21 mmHg in MAP, or
equivalently, a 5-unit increase in BMI was predicted to
produce an increase of approximately 1 mmHg in the
population MAP values (Fig. 5). This effect was inde-
pendent of time period and hypertensive status; that is,
regardless of the time period and hypertensive status,
the predicted BMI effect on MAP remained the same.
Parity was not statistically significant in any of the
studied models (p = 0.443 for the BMI model; p = 0.712
for the SBP model; p = 0.471for the DBP model; and p =
0.729 for the MAP model).
Discussion
Most of the normal increase in weight during preg-
nancy can be attributed to the foetus, breasts, and in-
creases in extravascular fluid, and it causes inevitable
demands on the hemodynamic balance of the preg-
nant. Consequently, blood pressure (BP) and maternal
weight measurements play a central role in the
Table 4 Estimates for the fixed and random effects identified by the (longitudinal) mixed-effects model for body mass index (BMI),
systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), and adjusted BMI effect on MAP (MAP-BMI),
in normotensive (NT) and chronic hypertensive (HT) women
Fixed effects Coefficient Standard error p-value Random effects Standard Deviation (95 % CI)
BMI Intercept 3.206 0.009 <0.001 Intercept 0.158 (0.117, 0.212)
HT (vs. NT) 0.124 0.034 <0.001 - -
Time 0.067 0.006 <0.001 - -
(Time)2 0.167 0.006 <0.001 - -
SBP Intercept 183.644 3.692 <0.001 Intercept 11.237 (10.058, 12.553)
HT (vs. NT) 16.034 1.166 <0.001 - -
Time −346.487 20.000 <0.001 Time 18.351 (16.601, 20.285)
(Time)2 539.023 32.389 <0.001 - -
(Time)3 −253.282 16.192 <0.001 - -
DBP Intercept 57.967 3.905 <0.001 Intercept 7.036 (5.702, 8.683)
HT (vs. NT) 11.954 0.974 <0.001 - -
Time 32.958 21.255 0.121 Time 15.327 (13.516, 17.380)
(Time)2 −63.105 35.012 0.072 - -
(Time)3 38.120 17.863 0.033 - -
MAP Intercept 96.181 2.902 <0.001 Intercept 6.719 (5.802, 7.780)
HT (vs. NT) 13.014 0.851 <0.001 - -
Time −74.081 15.754 <0.001 Time 12.745 (11.443, 14.196)
(Time)2 107.357 25.840 <0.001 - -
(Time)3 −44.409 13.116 0.001 - -
MAP-BMI Intercept 91.209 3.026 <0.001 Intercept 6.509 (5.604, 7.562)
HT (vs. NT) 12.283 0.837 <0.001 - -
BMI 0.210 0.039 <0.001 - -
Time −75.634 15.635 <0.001 Time 12.713 (11.422, 14.150)
(Time)2 108.038 25.629 <0.001 - -
(Time)3 −45.221 13.004 0.001 - -
The NT women were designated as the reference category
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adequate monitoring of pregnancy, during which
profound metabolic and circulatory changes occur
[13, 15, 21, 22]. These cardiovascular changes begin
early and include cardiac output increase, blood vol-
ume expansion, peripheral vasodilation and blood
pressure reduction. Notably, half of the cardiac out-
put increase occurs by 8 weeks of gestation, and
cardiac output increases to 30–50 % (1.8 L/min)
above the typical baseline (i.e., in non-pregnant sta-
tus) [23–25]. As a consequence, in early pregnancy
the uterus receives 3 to 6 % of the cardiac output,
whereas at 37–41 weeks it receives approximately 12
% of the cardiac output [26]. This increase is crucial
for an adequate perfusion of the developing feto-
placental unit [27–29].
The results from this prospective study showed that,
as in normotensive gestations [30, 31], in chronic
hypertensive pregnant women the shapes of the aver-
age SBP and MAP trajectories are characterized by a
decrease until mid-pregnancy followed by an increase
late in pregnancy. This pattern was much less notice-
able for DBP, where little and almost no decreases in
the average values were observed during pregnancy in
the NT and HT groups, respectively. In addition, the
differences in the SBP, DBP, and MAP trajectories
between the NT and HT groups remained constant
throughout pregnancy, and the trajectories temporally
progress in a parallel fashion.
To our knowledge, this is the first study to quantify
the effects of BMI on MAP in chronic hypertensive
pregnant women. We observed that higher BMI
values were associated with higher MAP values in all
trimesters of pregnancy in both the NT group and
the HT group. In addition, regardless of the time
period and hypertensive status, the predicted effect of
BMI on MAP remained the same; a 5-unit increase
in BMI was predicted to produce an increase of
approximately 1 mmHg in MAP.
Fig. 3 Expected systolic (SBP) and diastolic blood pressure (DBP) over time in the hypertensive and normotensive women. The 95 % confidence
intervals for the respective predictions are indicated (dashed lines)
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Overall, our findings are in line with the robust associ-
ation that has been found between increased adiposity
and higher blood pressure in humans [32–34]. Particu-
larly, previous studies have verified the blood pressure
pattern that occurs during the trimesters of pregnancy
in clinically healthy pregnant women [35–37] but not in
a population of chronic hypertensive pregnant women.
Statistics and methodological issues
In all of the models, the two mean curves had a narrow
95 % confidence interval. This suggests that most of the
variability was captured by the random effects, which
justifies their presence in the models. Moreover, the
presence of random effects and the modelling of their
variance-covariance structures competed with the cor-
relation structure of the errors, which turned out to have
a simple structure. This phenomenon is well-known in
the statistical literature on mixed-effects models [19].
The fact that the best variance-covariance structure of
the random effects was always a general positive definite
matrix is in line with the values of the estimated correl-
ation coefficients and variance estimates that were
obtained in the various models.
In the DBP model, the estimate for the time coefficient
was not statistically significant; however, this is irrelevant
because the estimates of the higher-order terms were all
significant.
No interactions between time and the hypertensive
status of the women were considered. This was
essentially due to the high-order polynomials (third
order) that we found for the time variable combined
with the sample size of the hypertensive group. There-
fore, the predicted mean curves for the hypertensive
population turned out to be a translation of the graph-
ical mean values that were predicted for the normoten-
sive population. However, this seemed to only negatively
impact the fitting within the hypertensive population in
the second evaluation period of the MAP model.
Within the MAP model, the residuals of the hyperten-
sive group were larger than those of the normotensive
group. This result was related to the strength of the
model, particularly the cubic time progression that ig-
nored the hypertensive status of the women, up to add-
ing a constant. The authors predicted that the presence
of interaction terms in the model would improve the
model predictions for the hypertensive population. How-
ever, this method would be inadequate given the rela-
tively low sample of hypertensive women. Nonetheless,
the sample size imbalance between the NT and HT par-
ticipants is in accordance with the prevalence of chronic
hypertension during pregnancy [7, 8].
The principal strength of this study was its prospective
longitudinal design, which allowed for the assessment of
data from the first trimester onwards. In addition, our
analyses are based on blood pressure and weight measure-
ments in the clinic (routine); therefore, they reflect the
patterns that occur in daily clinical practice as opposed to
assessments that are made during trial conditions [15].
Fig. 4 Expected mean arterial pressure (MAP) over time in the hypertensive (triangles) and normotensive (circles) women. The 95 % confidence
intervals for the respective predictions are indicated (dashed lines)
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Weight gain and hypertension
It is thought that weight gain causes hypertension [38, 39].
In fact, in the general population, many cohort studies in-
dicate that being overweight is a major risk factor for the
development of hypertension and that weight loss lowers
blood pressure in most hypertensive patients [1, 38]. This
phenomenon has been attributed to increases in weight-
related sympathetic activity, which in turn result in the
down-regulation of β-adrenergic receptors; this down-
regulation leads to a decreased thermogenic response and,
consequently, to an increased propensity for weight gain
and adiposity-related insulin resistance [40]. This hypoth-
esis has been strengthened by findings that hypertensive
subjects experience a generalized decrease in β-adrenergic
responsiveness, which modulates the development of
obesity in hypertension [41, 42]. As a corollary, sympa-
thetic overactivation leads to hypertension and weight
gain, and the weight gain further worsens the hyperten-
sion [38, 43]. Additionally, being overweight is a cause of
chronic inflammation and oxidative stress, which are in-
volved in the pathophysiology of hypertensive disorders
during pregnancy [44, 45].
Our results suggest that preventive strategies prior to
conception or adequate counselling during pregnancy
should be applied to prevent obesity in reproductive-age
women and to promote adequate increases in BMI dur-
ing pregnancy.
Study limitations
There are several limitations to our study that
should be acknowledged. First, the self-reporting of
information on many covariates was generally
avoided in this study, which limited the availability
of detailed information about a large number of po-
tential confounding factors, as certain adverse
lifestyle-related determinants of hypertension. Sec-
ond, information on maternal pre-pregnancy weight
was obtained through a questionnaire; thus, it
tended to be underestimated and we cannot exclude
the possibility of minor misclassification. Third, the
study comprised uneventful pregnancies, and thus
the results cannot be extrapolated to patients with
other forms of hypertensive disease during preg-
nancy. For the same reasons, we are not able to
analyse the effect of BMI gain and the risk of gesta-
tional hypertensive disorders or any adverse preg-
nancy outcomes. Fourth, we were not able to
measure MAP changes in relation to the distribution
of maternal fat, which is more related to endothelial
dysfunction, although BMI is highly correlated with
visceral fat [46]. Fifth, the generalizability of our in-
vestigation is also limited because our participants
were all White women. Sixth, because we did not as-
sess pregnancies with adverse outcomes, the clinical
relevance of our findings remains uncertain.
Fig. 5 Expected effects of body mass index on mean arterial pressure, at different time points during pregnancy, in the hypertensive
and normotensive pregnant women. Solid line, 12–14 weeks; dashed line, 18–22 weeks; dotted line, 29–33 weeks; dashed-dotted
line, at delivery. The effect is always the same, geometrically reflected on a unique slope, regardless of the time period and
hypertensive status
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Conclusions
This study provides evidence that in normotensive and
chronic hypertensive pregnant women, MAP is strongly
influenced by increases in BMI starting in the first
trimester and lasting until delivery.
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